A narrative review of research progress on drug therapies for glioblastoma multiforme.
A narrative review of research progress on drug therapies for glioblastoma multiforme.
复制标题
多形性胶质母细胞瘤药物治疗研究进展的叙述性综述。
DOI：
10.21037/atm-20-8017
复制
发表时间：
2021-06
影响因子：
--
通讯作者：
Du G
中科院分区：
文献类型：
--
作者：
Zheng X;Tang Q;Ren L;Liu J;Li W;Fu W;Wang J;Du G
多形性胶质母细胞瘤（GBM）是起源于中枢神经系统的恶性胶质瘤中最具侵袭性、最常见和最致命的亚型。目前，GBM的标准治疗是手术切除联合放疗和替莫唑胺（TMZ）。然而，该治疗仅将2年生存率从10%提高到26%，并伴有90%以上的GBM肿瘤在原部位复发。低生存率、严重的副作用和不良预后迫使人们寻找新的治疗方法。近年来，临床联合用药提高了GBM患者的生存率，但仍需发现高效低毒的新治疗药物。免疫治疗在肿瘤中的成功应用，为人们探索治疗GBM的新方法带来了希望。而不能穿过血脑屏障（BBB）、淋巴组织引流的损失和中枢神经系统中的抗原呈递细胞是免疫疗法在治疗GBM中失败的主要原因。胶质瘤干细胞（GSCs）是致瘤干细胞的一种亚型，具有更特异的致瘤潜能，靶向GSCs有望提高治疗效果。在这篇综述中，我们讨论了GBM患者受益的临床药物，GBM的癌症免疫治疗，总结了GBM的新药物靶点，并回顾了增加药物通过BBB的策略。
Glioblastoma multiforme (GBM) is the most aggressive, common, and lethal subtype of malignant gliomas originating from the central nervous system. Currently, the standard therapy for GBM is surgical resection combined with radiation and temozolomide (TMZ). However, the treatment only improves the 2-year survival rate from 10% to 26%, accompanied by more than 90% recurrence of GBM tumors at the original site. Low survival rate, serious side effects, and poor prognosis force people to find new therapies. Recent years, the combination of clinical drugs improves the survival rate of GBM patients, but new therapeutic drugs with high-efficiency and low-toxicity are still needed to be discovered. The successful use of immunotherapy in tumor brings hope for people to explore new methods in treating GBM. While the inability to cross the blood-brain barrier (BBB), loss of lymphatic tissue drainage, and antigen-presenting cells in the central nervous system are major reasons for the failure of immunotherapy in the treatment of GBM. Glioma stem cells (GSCs) is a subtype of tumorigenic stem cells which has more specific tumorigenic potential indicating targeting GSCs may be expected to improve therapeutic efficacy. In this review, we discuss clinical drugs that have benefited patients with GBM, cancer immunotherapy for GBM, summarize new drug targets of GBM, and review strategies for increasing the passage of drugs through the BBB.
登录
查看更多内容
影响因子：
6.2
作者：
Kawakami, M;Kawakami, K;Puri, RK
通讯作者：
Puri, RK
影响因子：
3.7
作者：
Brown CE;Warden CD;Starr R;Deng X;Badie B;Yuan YC;Forman SJ;Barish ME
通讯作者：
Barish ME
DOI：
10.1158/1078-0432.ccr-15-0428
发表时间：
2015-09-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Brown CE;Badie B;Barish ME;Weng L;Ostberg JR;Chang WC;Naranjo A;Starr R;Wagner J;Wright C;Zhai Y;Bading JR;Ressler JA;Portnow J;D'Apuzzo M;Forman SJ;Jensen MC
通讯作者：
Jensen MC
影响因子：
4.6
作者：
Kamran N;Calinescu A;Candolfi M;Chandran M;Mineharu Y;Asad AS;Koschmann C;Nunez FJ;Lowenstein PR;Castro MG
通讯作者：
Castro MG
影响因子：
4.5
作者：
Krebs, Simone;Chow, Kevin K. H.;Yi, Zhongzhen;Rodriguez-Cruz, Tania;Hegde, Meenakshi;Gerken, Claudia;Ahmed, Nabil;Gottschalk, Stephen
通讯作者：
Gottschalk, Stephen